<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Molar Pregnancy</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">

</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


  <!-- TOPIC AND IMAGE CONTAINER  -->

  <div class="hero-container" style="background: url('../images/heros/molar-pregnancy.png'); background-size: cover; background-position: center center;">
    <div class="hero-content">
      <h1>Molar Pregnancy</h1>
    </div>
  </div>

  <!-- END OF TOPIC AND IMAGE CONTAINER  -->
  


    <article class="notes">
        <a id='top'></a>
    <article>

      
            
                <div class="contributor-box">
                    <img class="contributor-avatar" src="../images/icons/drolusina.jpg" alt="Contributor 2 Avatar">
                    <div class="contributor-info">
                        <p class="contributor-description">Author</p>
                        <h3 class="contributor-name">Dr. Olusina D.O.</h3>
                        <div class="social-links">
                          <a href="https://wa.me/2348066872831" target="_blank" class="social-icon">
                            <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                        </a>

                        </div>
                    </div>
                </div>
            
        
          <!-- LEARNING OBJECTIVES CONTAINER  -->
              <div class="custom-card" id="custom-card-1">
                <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
                <div class="title"> 
                  <h2>What You Will Learn</h2>
                </div>
                <div class="line">
                  <p>After reading this note, you should be able to...</p>
                </div>
                <div class="content">
                  <ul>
                    <li><i>This content is not available yet.</i></li>
                </ul>
                </div>
                <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
              </div>
            
          <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
        
        
          <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
            <div class="outline2">
        
              <input type="radio" name="control-2" id="show-2">
              <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
              <input type="radio" name="control-2" id="hide-2">
              <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
              <div class="contents">
                <div class="icon-box">
                  <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                  <img src="../images/icons/book.png" alt="Icon" class="icon">
                </div>
                <div id="tableOfContents">
                    <ol id="tocList"></ol>
                </div>
              </div>
             <div>
        
        <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->
        
        
          <br>
        
            <!-- BEGINNING OF NOTE -->
        
      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'> Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li><strong>Gestational trophoblastic disease (GTD)</strong> refers to a spectrum of interrelated but histologically distinct tumors that originate from the placenta, with varied tendencies for invasion and spread.</li>

              <li><strong>Molar pregnancy</strong> represents a subtype of GTD.</li>
              <li>Arises from fetal tissue within the maternal host, with <strong>overproduction of chorionic tissue</strong>, which is normally supposed to develop into the placenta.</li>
              <li>Characterized by:
                <ul>
                  <li><strong>Hydropic swelling</strong> of the placental villi</li>
                  <li><strong>Hyperplasia</strong> of villous trophoblast</li>
                  <li><strong>Absent or abnormal fetal development</strong></li>
                </ul>
              </li>
              <li>Histologically, these tumors originate from <strong>syncytiotrophoblastic</strong> and <strong>cytotrophoblastic cells</strong>.</li>
              <li>Characterized by a reliable tumor marker: <strong>Œ≤-hCG</strong>.</li>
              <li>Known to be the <strong>first and only disseminated solid tumor</strong> proven to be highly curable by chemotherapy.</li>
              <li>Hence the dictum: <strong>‚ÄúGod‚Äôs first cancer and man‚Äôs first cure‚Äù</strong>.</li>
            </ul>
            
        </div>
      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Epidemiology</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
            <li>Incidence varies globally; generally <strong>1 per 1000 pregnancies</strong> worldwide.</li>
            <li>In high-income countries: <strong>1‚Äì3 per 1000 pregnancies</strong>.</li>
            <li>In East Asia: incidence is <strong>5- to 15-fold higher</strong>, approaching <strong>1 in 120 pregnancies</strong>.</li>
            <li>In West Africa, molar pregnancy incidence rates range between <strong>0.87 and 4.88 per 1000 deliveries</strong> in Nigeria.</li>
            <li>Ghana: <strong>0.80 per 1000 deliveries</strong>.</li>
            <li>Uganda: <strong>3.42 per 1000 deliveries</strong>.</li>
            <li>Tanzania: <strong> 12.8 per 1000 deliveries</strong>.</li>
            <li>Nnewi, Nigeria: <strong>4.7 per 1000 deliveries</strong>.</li>
            <li>Zaria, Nigeria: <strong>7.2 per 1000 deliveries</strong>.</li>
            </ul>


            </div>
          </section>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Classification of GTD</a>
          </h2>
        </header>
        <div class='body'>

            <!-- image here -->
            <div class="image-container">
                <img src="../figures/molar-pregnancy (1).jpg" alt="" onclick="openModal(this)">
                <div class="caption">Classification of GTD</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Classification of GTD</div>
              </div>


            <h4><strong>Molar Pregnancy (Hydatidiform Mole)</strong></h4>
            <ul>
              <li>The <strong>most common form</strong> of GTD.</li>
              <li><strong>Benign in nature</strong>.</li>
              <li>Classically, the chorionic villi show varying degrees of <strong>trophoblast proliferation</strong> and <strong>edema of the stroma</strong> within villi.</li>
              <li><strong>Chromosomal abnormalities</strong> play an integral role in the development of hydatidiform mole.</li>
              <li>Comprises <strong>complete</strong> and <strong>incomplete mole</strong> types.</li>
            </ul>
            
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Classification of Molar Pregnancy</a>
          </h2>
        </header>
        <div class='body'>
            <section id='heading-4-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-4-1'>Complete Mole</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                      <li><strong>Macroscopically</strong>, the chorionic villi are transformed into clusters of vesicles of varying dimensions, resembling a <strong>bunch of grapes</strong> ‚Äî hence the name <strong>hydatidiform mole</strong>.</li>
                      <li><strong>Microscopically</strong>, complete moles display <strong>enlarged, edematous villi</strong> and <strong>abnormal trophoblastic proliferation</strong>, which diffusely involves the entire placenta.</li>
                      <li><strong>No fetal tissue or amnion</strong> is produced.</li>
                      <li>As a result of these changes, the <strong>mass of placental tissue</strong> completely fills the <strong>endometrial cavity</strong>.</li>
                    </ul>
                    
                                <!-- image here -->
            <div class="image-container">
                <img src="../figures/molar-pregnancy (1).png" alt="" onclick="openModal(this)">
                <div class="caption">Types of CHM</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Types of CHM</div>
              </div>

              <h4><strong></strong></h4>
              <ul>
                <li>Complete mole arises when an <strong>empty ovum</strong> (with absent or inactivated nucleus) is fertilized by sperm.</li>
              </ul>
              
              <h4><strong>Homozygous Form</strong></h4>
              <ul>
                <li>Has two identical <strong>paternal chromosome complements</strong>, derived from duplication of the paternal haploid chromosomes.</li>
                <li>They are always <strong>46, XX</strong> and account for <strong>85‚Äì90%</strong> of complete hydatidiform moles (CHM).</li>
                <li><strong>46, YY</strong> has never been observed.</li>
              </ul>
              
              <h4><strong>Heterozygous Form</strong></h4>
              <ul>
                <li>Arises when an <strong>empty ovum</strong> is fertilized by <strong>two different sperms</strong> (dispermic fertilization).</li>
                <li>The chromosome complement can be <strong>46, XX</strong> or <strong>46, XY</strong>.</li>
                <li>Accounts for <strong>10‚Äì15%</strong> of complete moles.</li>
                <li>This diploid set is described as <strong>diandric</strong>.</li>
              </ul>
              
              <h4><strong>Biparental Complete Hydatidiform Mole (CHM)</strong></h4>
              <ul>
                <li><strong>Rare</strong> condition.</li>
                <li>Both <strong>maternal and paternal genes</strong> are present.</li>
                <li>Failure of <strong>maternal imprinting</strong> causes only the paternal genome to be expressed.</li>
                <li>A <strong>recurrent form</strong> of biparental mole has been described, which is <strong>familial</strong> and appears to be inherited as an <strong>autosomal recessive trait</strong>.</li>
                <li>A series of 5 women with as many as <strong>9 consecutive molar pregnancies</strong> has also been described.</li>
              </ul>
              
                <!-- image here -->
                <div class="image-container">
                    <img src="../figures/molar-pregnancy (2).png" alt="" onclick="openModal(this)">
                    <div class="caption">Although nuclear DNA is entirely paternal in CHM,
                        mitochondrial DNA remain maternal in origin.
                        </div>
                  </div>
                  
                  <div id="myModal" class="modal">
                    <span class="close" onclick="closeModal()">&times;</span>
                    <img class="modal-content" id="modalImage">
                    <div id="caption" class="caption">Although nuclear DNA is entirely paternal in CHM,
                        mitochondrial DNA remain maternal in origin.
                        </div>
                  </div>
              
                </div>
              </section>

              
                <section id='heading-4-2'>
                    <header>
                      <h3>
                        <a aria-hidden href='#heading-4-2'>Partial Hydatidiform Mole (PHM)</a>
                      </h3>
                    </header>
                    <div class='body'>
                        <ul>
                          <li>An ovum with an <strong>active nucleus</strong> is fertilized by a <strong>duplicated sperm</strong> or <strong>two haploid sperms</strong>.</li>
                          <li>Results in a zygote with a <strong>triploid set of chromosomes</strong>: <strong>69XXY (70%)</strong>, <strong>69XXX (27%)</strong>, or <strong>69XYY (3%)</strong>.</li>
                          <li><strong>YYY karyotype</strong> has not been observed.</li>
                          <li>In addition to placental tissue, partial moles contain <strong>fetal tissues</strong> and <strong>amnion</strong>.</li>
                          <li>Often associated with the development of an <strong>irregularly shaped, nonviable fetus</strong> with <strong>multiple malformations</strong> and <strong>abnormal growth</strong>.</li>
                        </ul>
                        
                        <h4><strong>PHM in Twin and Singleton Pregnancies</strong></h4>
                        <ul>
                          <li>In <strong>less than 25%</strong> of cases, PHM occurs with the development of an <strong>euploid viable fetus</strong>.</li>
                          <li>Most often presents as a <strong>twin pregnancy</strong> with one <strong>normal fetus</strong> and a <strong>complete molar pregnancy</strong>.</li>
                          <li>May also be a <strong>twin pregnancy</strong> with one normal fetus and an <strong>incomplete mole</strong>.</li>
                          <li>The rarest phenomenon is a <strong>singleton pregnancy</strong> with a <strong>chromosomally normal fetus</strong> and a <strong>partial molar placenta</strong>.</li>
                        </ul>
                        
                        <h4><strong>Clinical and Histological Features</strong></h4>
                        <ul>
                          <li>PHM often remains <strong>undiagnosed until histologic review</strong> of a curettage sample.</li>
                          <li>Typically ends in <strong>first trimester pregnancy loss</strong> as an <strong>incomplete or missed abortion</strong>.</li>
                          <li><strong>Histologically</strong>, the degree and extent of <strong>villous edema</strong> and <strong>trophoblastic proliferation</strong> are <strong>less pronounced</strong> than in complete mole.</li>
                          <li><strong>Uterine enlargement</strong> in excess of gestational age is <strong>uncommon</strong>.</li>
                          <li><strong>Œ≤-hCG levels</strong> and associated symptoms are <strong>less prominent</strong> than in complete mole.</li>
                        </ul>
                        
        
                    </div>
                  </section>

                  <section id='heading-4-3'>
                    <header>
                      <h3>
                        <a aria-hidden href='#heading-4-3'>Comparison of CHM & PHM</a>
                      </h3>
                    </header>
                    <div class='body'>


<br>
                        <table class="note-table">
                          <thead>
                            <tr>
                              <th><strong>Characteristic</strong></th>
                              <th><strong>Complete Mole (CHM)</strong></th>
                              <th><strong>Partial Mole (PHM)</strong></th>
                            </tr>
                          </thead>
                          <tbody>
                            <tr>
                              <td><strong>Karyotype</strong></td>
                              <td><strong>Diploid</strong> (46, XX, 46, XY)</td>
                              <td><strong>Triploid</strong> (69, XXX, 69, XXY)</td>
                            </tr>
                            <tr>
                              <td><strong>Embryo</strong></td>
                              <td><strong>Absent</strong></td>
                              <td><strong>Present</strong></td>
                            </tr>
                            <tr>
                              <td><strong>Villi Edema</strong></td>
                              <td><strong>Diffuse</strong> (Hydropic)</td>
                              <td><strong>Focal</strong> (Few Hydropic)</td>
                            </tr>
                            <tr>
                              <td><strong>Trophoblasts</strong></td>
                              <td><strong>Diffuse hyperplasia</strong></td>
                              <td><strong>Mild focal hyperplasia</strong></td>
                            </tr>
                            <tr>
                              <td><strong>Implantation-Site Trophoblast</strong></td>
                              <td><strong>Diffuse atypia</strong></td>
                              <td><strong>Focal atypia</strong></td>
                            </tr>
                            <tr>
                              <td><strong>Fetal RBCs</strong></td>
                              <td><strong>Absent</strong></td>
                              <td><strong>Present</strong></td>
                            </tr>
                            <tr>
                              <td><strong>Œ≤-hCG</strong></td>
                              <td><strong>High</strong> (>50,000)</td>
                              <td><strong>Slight elevation</strong> (<50,000)</td>
                            </tr>
                            <tr>
                              <td><strong>Frequency of Classical Symptoms</strong><br>
                                <ul>
                                    <li>Typical diagnosis</li>
                                    <li>Risk of persistent GTT</li>
                                </ul></td>
                              <td><strong>Common <br> 
                            <ul>
                                <li>Molar Pregnancy</li>
                                <li>20‚Äì30%</li>
                            </ul>
                        </strong></td>
                              <td><strong>Rare</strong> <br>
                            <ul>
                                <li><strong>Missed Abortion</strong></li>
                                <li><strong>&lt; 5%</strong></li>
                            </ul>
                            </td>
                            </tr>

                            <tr>
                              <td><strong>p57Kip2 Immunostaining</strong></td>
                              <td><strong>Negative</strong></td>
                              <td><strong>Positive</strong></td>
                            </tr>
                          </tbody>
                        </table>
                        
        
                    </div>
                  </section>
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Risk Factors</a>
          </h2>
        </header>
        <div class='body'>
            
            <ul>
              <li><strong>Age:</strong> Extremes of reproductive age (<strong>&lt; 20yrs</strong> and <strong>&gt; 40yrs</strong>).</li>
              <li><strong>Previous molar pregnancy</strong>.</li>
              <li><strong>Nulliparous women</strong>.</li>
              <li><strong>Low socio-economic status</strong>.</li>
              <li><strong>Diets deficient in protein, folic acid, and carotene</strong>.</li>
              <li><strong>Asian and black race</strong>.</li>
              <li><strong>Blood group A women</strong> impregnated by <strong>blood group O men</strong> (<strong>10-fold</strong> risk increase).</li>
              <li><strong>Blood group AB women</strong> have a relatively <strong>worse prognosis</strong>.</li>
              <li><strong>Familial</strong> tendency.</li>
            </ul>
            
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Clinical Features</a>
          </h2>
        </header>
        <div class='body'>

            <ul>
              <li><strong>Amenorrhea</strong>.</li>
              <li><strong>Abnormal uterine bleeding</strong>.</li>
              <li><strong>Most common symptoms</strong>: <strong>&gt; 90%</strong> of cases.</li>
              <li><strong>Hyperemesis</strong>: Seen in <strong>14‚Äì32%</strong> of cases.</li>
              <li><strong>Uterine size &gt; GA</strong>: Common with <strong>complete mole</strong>.</li>
              <li><strong>Bilateral theca lutein cysts</strong>: Seen in <strong>~15‚Äì30%</strong> of patients with molar pregnancy.</li>
              <li><strong>Preeclampsia</strong> in 1st or early trimester: <strong>Pathognomonic</strong> for hydatidiform mole, seen in <strong>10‚Äì12%</strong> of patients.</li>
              <li><strong>Hyperthyroidism</strong>: Seen in <strong>10%</strong> of patients.</li>
            </ul>
            
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'>Management </a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li><strong>Multidisciplinary approach</strong> involving the <strong>Gynaecologist</strong>, <strong>Radiologist</strong>, <strong>Histopathologist</strong>, <strong>Chemical pathologist</strong>, <strong>Geneticist</strong>, <strong>Clinical psychologist</strong>, <strong>Oncologist</strong>, <strong>Endocrinologist</strong>, and <strong>nurses</strong>.</li>
              <li><strong>History</strong></li>
              <li><strong>Examination</strong></li>
              <li><strong>Investigations</strong></li>
              <li><strong>Treatments</strong></li>
              <li><strong>Follow up</strong></li>
            </ul>

            <section id='heading-7-1'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-7-1'>History</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                      <li><strong>Abnormal uterine bleeding</strong>
                        <ul>
                          <li>Most common symptom ‚Äì <strong>bright red or brownish</strong></li>
                          <li>Occurs in <strong>&gt;90%</strong> of patients with molar pregnancy</li>
                          <li><strong>Passage of vesicles</strong></li>
                        </ul>
                      </li>
                      <li><strong>Nausea and vomiting</strong>
                        <ul>
                          <li>Occurs in <strong>14‚Äì32%</strong> of patients with hydatidiform mole</li>
                          <li>May be confused with <strong>hyperemesis gravidarum</strong></li>
                        </ul>
                      </li>
                      <li><strong>Previous history of GTD</strong></li>
                      <li><strong>Passage of grape-like tissue</strong></li>
                      <li><strong>Lower abdominal pain</strong> ‚Äì may be absent in early diagnosis</li>
                    </ul>
                    
    
                </div>
              </section>

              <section id='heading-7-2'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-7-2'>Examination</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                      <li><strong>General</strong> ‚Äì may be <strong>anxious</strong>, <strong>pale</strong>, <strong>dehydrated</strong> +/- <strong>pedal edema</strong></li>
                      <li>Signs of <strong>thyrotoxicosis</strong> may be present</li>
                      <li><strong>CVS</strong> ‚Äì <strong>tachycardia</strong>, <strong>BP normal or elevated</strong>, <strong>hyperactive precordium</strong>, signs of <strong>heart failure</strong> from hyperthyroidism</li>
                      <li><strong>Abdomen</strong> ‚Äì <strong>doughy uterus</strong>; size may be:
                        <ul>
                          <li><strong>Large for date</strong> in 50% of cases</li>
                          <li><strong>Smaller</strong> in 30% of cases</li>
                        </ul>
                      </li>
                      <li><strong>Pelvic examination</strong>
                        <ul>
                          <li><strong>Blood smeared vulva</strong></li>
                          <li><strong>Adnexal mass</strong> (theca lutein cyst)</li>
                          <li>+/- <strong>adnexal tenderness</strong> (cyst accident)</li>
                        </ul>
                      </li>
                    </ul>
    
                </div>
              </section>

              <section id='heading-7-3'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-7-3'>Investigations</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                      <li><strong>Serum pregnancy test (PT)</strong></li>
                      <li><strong>Quantitative serum Œ≤-hCG</strong></li>
                      <li><strong>FBC + differentials</strong> (urgent PCV)</li>
                      <li><strong>Coagulation studies</strong></li>
                      <li><strong>Liver function test (LFT)</strong></li>
                      <li><strong>Electrolytes, Urea, Creatinine (E/U/Cr)</strong></li>
                      <li><strong>Urinalysis</strong></li>
                      <li><strong>Blood group, Rhesus factor, Group and Crossmatch (GXM)</strong></li>
                    </ul>
    
                    <h4><strong>Imaging and Laboratory Evaluation</strong></h4>
                    <ul>
                      <li><strong>Ultrasound</strong>
                        <ul>
                          <li><strong>Snowstorm appearance</strong></li>
                          <li>In <strong>partial mole</strong>: focal trophoblastic changes and fetal tissue may be noted</li>
                          <li><strong>Theca lutein cyst</strong> may be seen</li>
                        </ul>
                      </li>
                      <li><strong>Chest X-ray</strong> ‚Äì baseline film after diagnosis of molar pregnancy</li>
                      <li><strong>Histology</strong></li>
                      <li><strong>Karyotyping</strong> ‚Äì identifies <strong>triploidy</strong></li>
                    </ul>
            <!-- image here -->
            <div class="image-container">
                <img src="../figures/molar-pregnancy (1).gif" alt="" onclick="openModal(this)">
                <div class="caption">CHM USS FINDINGS- Snowstorm appearance</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">CHM USS FINDINGS- Snowstorm appearance</div>
              </div>

                          <!-- image here -->
            <div class="image-container">
                <img src="../figures/molar-pregnancy (2).gif" alt="" onclick="openModal(this)">
                <div class="caption">CHM USS FINDINGS- THECA LUTEIN CYST</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">CHM USS FINDINGS- THECA LUTEIN CYST</div>
              </div>

                          <!-- image here -->
            <div class="image-container">
                <img src="../figures/molar-pregnancy (5).jpg" alt="" onclick="openModal(this)">
                <div class="caption">PHM USS FINDINGS</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">PHM USS FINDINGS</div>
              </div>


                </div>
              </section>

              <section id='heading-7-4'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-7-4'>Treatment</a>
                  </h3>
                </header>
                <div class='body'>
                    <h4><strong>Treatment of CHM</strong></h4>
                    <ul>
                      <li><strong>Resuscitate</strong> the patient and treat medical complications <strong>before evacuation</strong>.</li>
                      <li><strong>Treatment should not be delayed</strong>‚Äîoften initiated even before histological confirmation.</li>
                      <li><strong>Suction evacuation</strong> is the preferred method for hydatidiform mole.</li>
                      <li>It is <strong>safe, rapid, and effective</strong> in nearly all cases.</li>
                    </ul>
                    
                    <h4><strong>Preparatory Steps</strong></h4>
                    <ul>
                      <li>Ensure the patient is <strong>properly evaluated and fit for surgery</strong>.</li>
                      <li><strong>Group and crossmatch (GXM) blood</strong>.</li>
                      <li><strong>Obtain informed consent</strong>.</li>
                      <li>Prepare (ripen) the cervix using <strong>physical dilators</strong> or <strong>prostaglandins</strong>.</li>
                      <li><strong>Administer appropriate anaesthesia</strong>:
                        <ul>
                          <li><strong>General anaesthesia (GA)</strong> is preferred.</li>
                          <li><strong>Local anaesthesia (LA)</strong> may be used in stable patients with small uterine size.</li>
                        </ul>
                      </li>
                    </ul>
                    
                    <h4><strong>Suction Evacuation Procedure</strong></h4>
                    <ul>
                      <li><strong>Assemble instruments</strong>, scrub, and gown.</li>
                      <li>Place the patient in <strong>lithotomy position</strong>, clean and drape appropriately.</li>
                      <li><strong>Empty the bladder</strong>.</li>
                      <li><strong>Assess uterine size</strong> and <strong>cervical dilation</strong> via bimanual exam.</li>
                      <li>Insert <strong>Sim‚Äôs speculum</strong> to expose cervix.</li>
                      <li>Grasp cervix with <strong>vulsellum</strong> and straighten the cervical canal.</li>
                      <li>Insert a <strong>suction cannula</strong> (usually <strong>12‚Äì14 mm</strong>, smaller than uterine size), should reach just beyond the internal os.</li>

                      <li><strong>Connect cannula</strong> to suction machine and switch on.</li>
                      <li>Start <strong>oxytocin infusion</strong> toward the end or midway through the procedure.</li>
                      <li><strong>Completeness</strong> is indicated by a <strong>gritty sensation</strong> and presence of <strong>frothy blood</strong>.</li>
                      <li><strong>Disconnect suction</strong> machine.</li>
                      <li>Perform <strong>gentle sharp curettage</strong>.</li>
                      <li>Remove all instruments and ensure <strong>haemostasis</strong>.</li>
                      <li><strong>Clean the patient</strong> and reposition.</li>
                      <li>Transfer to the <strong>recovery room</strong> and monitor post-op condition.</li>
                      <li><strong>Document findings</strong> thoroughly.</li>
                      <li><strong>Send tissue samples</strong> for histological examination.</li>
                      <li><strong>Administer anti-D prophylaxis</strong> to <strong>Rhesus-negative women</strong> after evacuation.</li>
                      <li><strong>Rhesus D antigen</strong> is expressed on the trophoblast.</li>
                      <li><strong>Cervical dilation</strong> should admit a <strong>10‚Äì12 mm plastic curette</strong>.</li>
                      <li><strong>Ultrasound-guided suction evacuation</strong> is preferred to minimize uterine perforation and confirm completeness.</li>
                      <li><strong>Partial mole</strong> may require a <strong>combination of medical and surgical treatment</strong>.</li>
                      <li><strong>Oxytocics</strong> should <strong>not be used prior to evacuation</strong>:
                        <ul>
                          <li>May be considered in cases of significant haemorrhage.</li>
                          <li>Weigh the <strong>risk of oxytocin use</strong> against the possibility of <strong>tissue embolism</strong>.</li>
                          <li><strong>Do not commence oxytocin before evacuation begins.</strong></li>
                        </ul>
                      </li>
                    </ul>
                    
                    <h4><strong>Complications</strong></h4>

                    
                    <ul>
                        <li><strong>Hemorrhage</strong>

                        <ul>
                            <li>In cases of <strong>large hydatidiform mole (HM) &gt; 12 weeks</strong>, a <strong>laparotomy setup</strong> should be readily available.</li>
                            <li><strong>Hysterotomy or hysterectomy</strong> may be necessary in such cases.</li>
                          </ul>
                      <li><strong>Uterine perforation</strong>
                        <ul>
                          <li>May occur because the uterus is <strong>large and boggy</strong>.</li>
                          <li>If perforation is noted, the procedure should be completed under <strong>laparoscopic guidance</strong>.</li>
                        </ul>
                      </li>
                      <li><strong>Trophoblastic embolism</strong>
                        <ul>
                          <li>May cause <strong>acute respiratory insufficiency</strong>.</li>
                          <li>Avoid oxytocics before onset of uterine evacuation</li>
                        </ul>
                      </li>
                    </ul>
                    
                    <h4><strong>Hysterectomy</strong></h4>
                    <ul>
                      <li><strong>Rarely recommended</strong>, but indicated in:
                        <ul>
                          <li>Patients desiring <strong>surgical sterilization</strong></li>
                          <li>Women <strong>approaching menopause</strong></li>
                        </ul>
                      </li>
                      <li>Eliminates the risk of <strong>local myometrial invasion</strong> as a cause of persistent mole.</li>
                      <li><strong>Reduces risk</strong> of malignant postmolar sequelae to approximately <strong>3‚Äì5%</strong> compared with <strong>15‚Äì20%</strong> after suction evacuation.</li>
                      <li><strong>Does not eliminate</strong> the need for <strong>careful follow-up with Œ≤-hCG testing</strong>.</li>

                      <li><strong>Theca lutein cysts</strong> may be incidental findings during hysterectomy.</li>
                      <li><strong>Adnexa can be preserved bilaterally</strong> if cysts are present.</li>
                      <li><strong>Surgical treatment</strong> is indicated only in cases of:
                        <ul>
                          <li><strong>Rupture</strong></li>
                          <li><strong>Torsion</strong></li>
                          <li><strong>Infection</strong></li>
                          <li><strong>Hemorrhage</strong></li>
                        </ul>
                      </li>
                    </ul>
                    
                </div>
              </section>

              <section id='heading-7-5'>
                <header>
                  <h3>
                    <a aria-hidden href='#heading-7-5'>Follow-Up</a>
                  </h3>
                </header>
                <div class='body'>
                    <ul>
                      <li><strong>The most essential aspect</strong> of patient management.</li>
                      <li>Incidence of <strong>malignant transformation</strong> is approximately <strong>20‚Äì30%</strong>.</li>
                      <li><strong>1‚Äì2 weekly serial hCG</strong> determinations should begin within <strong>48 hours after evacuation</strong>, and continue until <strong>three consecutive tests</strong> show normal hCG levels (<strong>&lt;5 mIU/mL</strong>).</li>
                      <li>This should be continued weekly until <strong>hCG declines to undetectable levels</strong> on three successive assays.</li>
                      <li>For complete mole:
                        <ul>
                          <li>If hCG reverts to normal (<strong>&lt;5 IU/mL</strong>) within <strong>56 days (8 weeks)</strong> of evacuation, follow-up continues for <strong>6 months from the day of evacuation</strong>.</li>
                          <li>If hCG does <strong>not revert to normal within 56 days</strong>, follow-up is for <strong>6 months from the normalization of hCG levels</strong>.</li>
                        </ul>
                      </li>
                      <li>For <strong>partial mole</strong>, follow-up can be concluded once hCG returns to normal on <strong>two samples at least 4 weeks apart</strong>.</li>
                      <li><strong>Avoid pregnancy</strong> during follow-up, ideally <strong>until 6 months after the first normal hCG result</strong>.</li>
                      <li><strong>Oral contraceptives</strong> are preferred due to their ability to <strong>suppress endogenous luteinizing hormone (LH)</strong>, which may interfere with hCG measurement.</li>
                      <li><strong>Gynaecological exams</strong> during follow-up should assess:
                        <ul>
                          <li>Uterine size</li>
                          <li>Presence of theca lutein cysts</li>
                          <li>Presence of vulvar, vaginal, or cervical lesions</li>
                        </ul>
                      </li>
                      <li>Repeat examination <strong>at 4-week intervals</strong> throughout the observation period.</li>
                      <li><strong>Good prognostic signs</strong> include:
                        <ul>
                          <li>Uterine involution</li>
                          <li>Regression of theca-lutein cysts</li>
                          <li>Cessation of vaginal bleeding</li>
                        </ul>
                      </li>
                    </ul>
                    
    
                </div>
              </section>
        </div>
      </section>

      <section id='header-8'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'> Post-Evacuation Treatment</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Indicated when there is evidence of persistent GTD (referred to as GTN).</li>
              <li>Criteria include:
                <ul>
                  <li>Plateau of hCG over <strong>4 measurements across ‚â•3 weeks</strong></li>
                  <li><strong>hCG > 20,000 IU/L</strong> persisting 4+ weeks post-evacuation</li>
                  <li>Persisting uterine haemorrhage</li>
                  <li>Progressively increasing hCG at any point post-evacuation</li>
                  <li>Elevated hCG still present 6 months post-evacuation, even if decreasing</li>
                  <li>Histological diagnosis of choriocarcinoma</li>
                  <li>Evidence of metastases, regardless of hCG level</li>
                </ul>
              </li>
              <li><strong>Risk of requiring chemotherapy:</strong>
                <ul>
                  <li><strong>13‚Äì16%</strong> in complete hydatidiform mole (CHM)</li>
                  <li><strong>0.5‚Äì1.0%</strong> in partial molar pregnancy</li>
                </ul>
              </li>
            </ul>
            
            <h4><strong>Prophylactic Chemotherapy</strong></h4>
            <ul>
              <li>May be considered in <strong>‚Äòat risk‚Äô women</strong> to prevent progression to GTN.</li>
              <li>‚ÄòAt risk‚Äô factors include:
                <ul>
                  <li>Age > 35 years</li>
                  <li>Initial serum hCG > 100,000 IU/mL</li>
                  <li>Failure of hCG normalization by 7‚Äì9 weeks post-evacuation</li>
                  <li>Histological diagnosis of infiltrative mole</li>
                  <li>Post-evacuation haemorrhage</li>
                  <li>Evidence of metastases irrespective of the level of hCG</li>
                  <li>Previous molar pregnancy</li>
                  <li>Patient unlikely to adhere to follow-up</li>
                </ul>
              </li>
              <li><strong>Disadvantage:</strong> Potential overtreatment-unnecessary exposure to chemotherapy, as 80‚Äì90% of women do not develop GTN.</li>
            </ul>
            
            <h4><strong>Psychological Effect</strong></h4>
            <ul>
              <li>Molar pregnancy diagnosis can cause short-term psychological effects.</li>
              <li>Common presentations include:
                <ul>
                  <li><strong>Anxiety disorders</strong></li>
                  <li><strong>Depressive disorders</strong></li>
                  <li><strong>Moderate to severe adaptational problems</strong></li>
                  <li><strong>Reproductive concerns</strong>, especially regarding fertility</li>
                </ul>
              </li>
              <li>Women who already have children often experience:
                <ul>
                  <li>Less concern about fertility</li>
                  <li>Lower levels of psychological distress</li>
                </ul>
              </li>
            </ul>
            
        </div>
      </section>

      <section id='header-9'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-9'> Differential Diagnosis/Other phenomenon</a>
          </h2>
        </header>
        <div class='body'>
            <h4><strong></strong></h4>
            <ul>
              <li>Hyperemesis Gravidarum</li>
              <li>Incomplete abortion</li>
              <li>Ectopic pregnancy</li>
              <li>Hypertension</li>
              <li>Hyperthyroidism and Thyrotoxicosis</li>
            </ul>
            
            <h4><strong>Hook Effect</strong></h4>
            <ul>
              <li>A rare phenomenon</li>
              <li>Gives a false negative result at very high levels of Œ≤-hCG (usually &gt;500,000 mIU/ml)</li>
              <li>There‚Äôs improper antigen-antibody ratio</li>
              <li>Normally, Œ≤-hCG binds to a capture molecule</li>
              <li>The ‚Äúcaptured‚Äù molecule is then read by the assay against a standard concentration curve, to read as positive or negative</li>
              <li>In Hook effect, the amount of Œ≤-hCG is so high that it overwhelms the capture molecule</li>
              <li>Overcome by urine PT in serial dilution</li>
            </ul>
            
            <h4><strong>Phantom hCG</strong></h4>
            <ul>
              <li>Gives a false positive result, due to heterophillic antibodies</li>
              <li>Persistently +ve hCG in a non-pregnant patient</li>
              <li>Often leads to a false diagnosis of malignancy and inappropriate treatment with chemotherapy or hysterectomy</li>
              <li>Heterophyllic antibodies are large and filtered by the glomerulus</li>
              <li>A quantitative serum hCG should be run in conjunction with a urine hCG (qualitative or quantitative)</li>
              <li>A +ve quantitative serum hCG coupled with a -ve urine hCG is supportive of the diagnosis of phantom hCG</li>
              <li>Urine hCG should be performed in all cases of persistent or irregular vaginal bleeding lasting more than 8 weeks after a pregnancy event</li>
            </ul>
            
            <h4><strong>Twinning</strong></h4>
            <ul>
              <li>Twinning with a complete mole and a fetus with a normal placenta has been reported</li>
              <li>Cases of healthy infants in these circumstances have been reported</li>
              <li>Women with coexistent molar and normal gestations are at higher risk for developing persistent disease and metastasis</li>
              <li>Termination of pregnancy is a recommended option</li>
              <li>Continue pregnancy if maternal status is stable, without hemorrhage, thyrotoxicosis, or severe hypertension</li>
              <li>Patient should be informed of the risk of severe maternal morbidity from possible complications</li>
              <li>Prenatal genetic diagnosis by CVS or amniocentesis is recommended to evaluate</li>
            </ul>
            
            <h4><strong>Familial Recurrent Hydatidiform Mole (FRHM)</strong></h4>
            <ul>
              <li>Extremely rare (reported in only 21 families in the medical literature)</li>
              <li>In these cases, the HM are diploid, but bi-parental, unlike the androgenetic origin of sporadic complete moles</li>
              <li>These patients have an autosomal recessive condition that results in recurrent molar pregnancies with little chance of a successful pregnancy</li>
              <li>Patients with a personal, but no family history of recurrent moles usually have androgenetic CHM</li>
              <li>Two gene mutations, <em>NLRP7</em> and <em>KHDC3L</em>, account for ‚àº75% and 5% of the affected cases, respectively</li>
              <li>Normal pregnancy is achieved by IVF with pre-gestational diagnosis in the sporadic type, but with donor egg in FRHM</li>
            </ul>
            
        </div>
      </section>

      <section id='header-10'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-10'>Prognosis </a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Molar pregnancy has excellent prognosis, if diagnosed and treated early</li>
              <li>Potential for child bearing can be preserved</li>
              <li>With early diagnosis and appropriate treatment, the current mortality rate from hydatidiform mole is essentially zero</li>
              <li>Approximately 20% of women with a complete mole develop a trophoblastic malignancy (&lt;5% in partial mole)</li>
              <li>Even when GTN develops, it is almost 100% curable</li>
            </ul>
            
        </div>
      </section>

      <section id='header-11'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-11'> Conclusion</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Molar pregnancy is a significant form of GTD whose management requires a multidisciplinary approach with prompt diagnosis and management to prevent complications and ensure optimal outcomes.</li>
              <li>Hence, early detection and recognition through clinical signs, confirmatory investigations such as ultrasound scan and histology, as well as monitoring hCG levels post-evacuation to detect persistent disease, is very crucial.</li>
              <li>With appropriate treatment and follow-up, prognosis is generally favourable.</li>
              <li>However, continued research and awareness are essential to improving diagnosis techniques and patient care in cases of molar pregnancy.</li>
            </ul>
            
        </div>
      </section>

      






      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://docs.google.com/forms/d/e/1FAIpQLSdx2teDCmW6ivSeKLQg7zF_jy7Yfg_1Gqm84_UT0PQPATsNug/viewform?usp=sf_link" class="comment-button">
            here
            <!-- <img src="../images/icons/whatsapp.png" alt="Image Icon"> -->
          </a>
        </div>


      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>

<!-- Floating TOC Button -->
<div id="toc-button" class="floating-toc-button">
  Table of Contents
</div>

<!-- Expandable TOC Panel -->
<div id="toc-panel" class="toc-panel">
  <div id="toc-panel-content">
      <h4>Table of Contents</h4>
      <ol id="dynamic-toc"></ol>
  </div>
</div>



<script>
// Dynamically generate TOC from <h2> headings within <section> elements
  const tocList = document.getElementById('dynamic-toc');
const sections = document.querySelectorAll('section');
const tocButton = document.getElementById('toc-button');
const tocPanel = document.getElementById('toc-panel');

// Generate Table of Contents
sections.forEach(section => {
    const headings = section.querySelectorAll('h2');
    headings.forEach(heading => {
        const headingAnchor = heading.querySelector('a');
        if (headingAnchor && headingAnchor.getAttribute('href')) {
            const tocItem = document.createElement('li');
            const link = document.createElement('a');
            link.textContent = headingAnchor.textContent || 'Untitled Section';
            link.href = headingAnchor.getAttribute('href');
            tocItem.appendChild(link);
            tocList.appendChild(tocItem);
        }
    });
});

// Hide TOC button initially
tocButton.style.display = 'none';

// Show/hide TOC button on scroll
window.addEventListener('scroll', () => {
    // Show button after scrolling down 200 pixels
    if (window.scrollY > 200) {
        tocButton.style.display = 'block';
    } else {
        tocButton.style.display = 'none';
        tocPanel.classList.remove('expanded');
    }
});

// Toggle TOC panel
tocButton.addEventListener('click', (event) => {
    event.stopPropagation(); // Prevent immediate closure
    tocPanel.classList.toggle('expanded');
});

// Close TOC panel when clicking outside
document.addEventListener('click', (event) => {
    if (tocPanel.classList.contains('expanded') && 
        !tocPanel.contains(event.target) && 
        event.target !== tocButton) {
        tocPanel.classList.remove('expanded');
    }
});


</script>

</body>
</html>
 
